Jak/Stat Pathway
IL-1RA (20D8) Mouse mAb
|
イイネ！(1)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #3865S | 100 μL | 46,000 | |
|
3865 の推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
3865:
-
Western Blotting
| 用途（希釈倍率） | |
| ウェスタンブロッティング（1:1,000） |
| 特異性・感度 | |
| 内在性レベルのIL-1RA タンパク質を検出します。他の関連するタンパク質とは交差しません。 |
Western Blotting
Western blot analysis of variable amounts of recombinant human IL-1RA protein and A431 cell lysate using IL-1RA (20D8) Mouse mAb.
The founding members of the interleukin-1 (IL-1) superfamily include pro-inflammatory cytokines IL-1α and IL-1β, and a third protein that acts as an IL-1 receptor antagonist (IL-1RA). At least six similar proteins have been recently identified, including a homolog of IL-1RA (IL1F5). The three better-characterized proteins (IL-1a, IL-1b and IL-1RA) are mainly expressed in macrophages, monocytes, and dendritic cells. IL-1a and IL-1b act as potent inflammatory cytokines that help regulate host defense and immune responses (1). Binding of these pro-inflammatory cytokines to an IL-1 receptor recruits adapter proteins (such as IRAK) to the receptor. Phosphorylation of these adaptor proteins promotes downstream signaling cascades associated with the immune response (2). Altered expression of both IL-1a and IL-1b is associated with an extensive list of human disorders, including Alzheimer's disease, rheumatoid arthritis, psoriasis and various forms of cancer (3,4). IL-1RA acts as an anti-inflammatory cytokine, binding the IL-1 receptor to limit the response to inflammation (5). Because it plays a key role in regulating the inflammatory response, recombinant IL-1RA is a therapeutic agent used in the treatment of diseases such as rheumatoid arthritis. Alternatively, mutation of the corresponding IL-1RA gene may be associated with susceptibility to the development of specific cancers (6).
-
Pelegrin, P. (2008) Drug News Perspect 21, 424-33.
-
Ringwood, L. and Li, L. (2008) Cytokine 42, 1-7.
-
Griffin, W.S. and Mrak, R.E. (2002) J Leukoc Biol 72, 233-8.
-
Kamangar, F. et al. (2006) Cancer Epidemiol Biomarkers Prev 15, 1920-8.
-
Arend, W.P. Cytokine Growth Factor Rev 13, 323-40.
-
Sehouli, J. et al. Anticancer Res 22, 3421-4.
PhosphoSitePlus®：
IL1RN